Millennium Pharmaceuticals Limited

Rachel A Meyers

Laura A Rudolph-Owen

Rosana Kapeller-Libermann

Rory A J Curtis

Nadine Weich

John J Hunter

The invention provides isolated nucleic acids molecules, designated 2504, 15977, or 14760 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, or 14760 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, or 14760 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, or 14760 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, or 14760 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

2504, 15977, and 14760, novel protein kinase family members and uses therefor

Novel cytidine deaminase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length cytidine deaminase-like proteins, the invention further provides isolated cytidine deaminase-like fusion proteins, antigenic peptides, and anti-cytidine deaminase-like antibodies. The invention also provides cytidine deaminase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an cytidine deaminase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

26934, a novel cytidine deaminase-like molecule and uses thereof

The invention provides isolated nucleic acids molecules, designated 38692 or 21117 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38692 or 21117 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38692 or 21117 gene has been introduced or disrupted. The invention still further provides isolated 38692 or 21117 proteins, fusion proteins, antigenic peptides and anti-38692 or 21117 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

38692 and 21117, novel dual specificity phosphatase molecules and uses therefor

Novel ATPase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ATPase-like proteins, the invention further provides isolated ATPase-like fusion proteins, antigenic peptides, and anti-ATPase-like antibodies. The invention also provides ATPase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ATPase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

7970, a novel ATPase-like molecule and uses thereof

The present invention relates to a newly identified human PGP synthase. The invention also relates to polynucleotides encoding the PGP synthase. The invention further relates to methods using the PGP synthase polypeptides and polynucleotides as a target for diagnosis and treatment in POP synthase-mediated or -related disorders. The invention further relates to drug-screening methods using the POP synthase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the POP synthase polypeptides and polynucleotides. The invention further relates to procedures for producing the POP synthase polypeptides and polynucleotides.

27411, a novel human PGP synthase

The invention provides isolated nucleic acids molecules, designated 22406 nucleic acid molecules, which encode a novel pyridoxal-phosphate dependent serine racemase. In particular, the invention relates to 22406 serine racemase polypeptide and encoding nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22406 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22406 gene has been introduced or disrupted. The invention still further provides isolated 22406 proteins, fusion proteins, antigenic peptides and anti-22406 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

22406, a novel human pyridoxal-phosphate dependent enzyme family member and uses therefor

The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

Growing community of inventors

Newton, MA, United States of America

Rachel A Meyers